# Giuseppe Tonini

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/giuseppe-tonini/

## Facts

| Field | Value |
| --- | --- |
| Citations | 33,643 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 84 |
| i10-index | 412 |
| Last Known Institution | Università Campus Bio-Medico |
| OpenAlex ID | https://openalex.org/A5059367989 |
| ORCID iD | https://orcid.org/0000-0003-4442-8677 |
| Works | 1,155 |

## Researcher papers

- [Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis](https://scholariq.org/papers/effects-of-kras-braf-nras-and-pik3ca-mutations-on-the-efficacy-of-cetuximab-plus/)
- [FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study](https://scholariq.org/papers/folfoxiri-plus-bevacizumab-versus-folfiri-plus-bevacizumab-as-first-line/)
- [Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer](https://scholariq.org/papers/initial-therapy-with-folfoxiri-and-bevacizumab-for-metastatic-colorectal-cancer/)
- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-lenvatinib-plus-placebo-for-advanced/)
- [PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer](https://scholariq.org/papers/pten-expression-and-kras-mutations-on-primary-tumors-and-metastases-in-the/)
- [Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.](https://scholariq.org/papers/pamidronate-induces-modifications-of-circulating-angiogenetic-factors-in-cancer/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Bone health and treatments](https://scholariq.org/topics/bone-health-and-treatments/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

## Researcher university

- [Università Campus Bio-Medico](https://scholariq.org/institutions/universita-campus-bio-medico/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.